Who Owns Edgewise Therapeutics Company?

Edgewise Therapeutics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Edgewise Therapeutics?

Understanding Edgewise Therapeutics' ownership is key to grasping its strategic direction and R&D priorities. This clinical-stage biopharmaceutical company focuses on rare muscle disorders like Duchenne muscular dystrophy.

Edgewise Therapeutics, founded in 2017, aims to develop small molecule therapies for unmet medical needs in muscle disorders. Its mission is to bring innovative treatments to patients suffering from conditions like DMD and Becker muscular dystrophy.

Edgewise Therapeutics went public on March 26, 2021, on the Nasdaq Global Select Market under the ticker EWTX. The IPO raised approximately $176.0 million. As of August 15, 2025, the company's market capitalization is around $1.49 billion. This growth reflects its progress in developing potential treatments, including its lead candidate for Duchenne muscular dystrophy, which is detailed in the Edgewise Therapeutics PESTEL Analysis.

Edgewise Therapeutics was established in 2017 by a group of accomplished scientists and entrepreneurs, including Badreddin Edris, Alan Russell, and Peter A. Thompson. These founders brought significant expertise to the company's inception, laying the groundwork for its future development and operations.

Founding Team

Edgewise Therapeutics was founded in 2017 by Badreddin Edris, Alan Russell, and Peter A. Thompson, bringing together scientific and entrepreneurial talent.

Key Leadership

Dr. Alan Russell leads as Chief Scientific Officer, while Dr. Peter Thompson, a Partner at OrbiMed, chairs the Board. Kevin Koch, Ph.D., joined in 2017 as President and CEO.

Early Investment Rounds

The company raised a total of $145 million across two significant funding rounds before its IPO.

Series B Funding

A Series B round on September 17, 2019, secured $50 million, with notable participation from investors like Novo Holdings and USVP.

Series C Funding

The Series C round, completed on December 8, 2020, brought in $95 million, led by Viking Global Investors with Janus Henderson Investors also involved.

Impact of Early Funding

These early investments were vital for advancing the company's drug discovery platform and initial clinical programs.

The early ownership structure of Edgewise Therapeutics was significantly shaped by its initial funding rounds, attracting substantial capital from venture capital and institutional investors. While precise equity distribution at the company's inception is not publicly disclosed, the substantial investments made by firms such as Novo Holdings, USVP, Viking Global Investors, and Janus Henderson Investors indicate that these entities held significant early ownership stakes. These financial commitments were instrumental in fueling the company's research and development efforts, supporting its proprietary drug discovery platform and the progression of its early clinical programs. Understanding these early investors is key to grasping the initial ownership landscape of Edgewise Therapeutics, a crucial aspect of its company history and Growth Strategy of Edgewise Therapeutics.

Edgewise Therapeutics Early Ownership Overview

The foundational ownership of Edgewise Therapeutics was established through its founding team and subsequent significant investments from prominent venture capital and institutional players.

• Founders: Badreddin Edris, Alan Russell, and Peter A. Thompson.
• Key Executive: Kevin Koch, Ph.D., joined as President and CEO in 2017.
• Total Early Funding: $145 million raised prior to IPO.
• Key Investors: Novo Holdings, USVP, Viking Global Investors, and Janus Henderson Investors.

Edgewise Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Since its initial public offering on March 26, 2021, Edgewise Therapeutics (NASDAQ: EWTX) has experienced shifts in its ownership landscape. A significant capital raise in April 2025 further influenced the distribution of its shares.

As of August 18, 2025, a substantial portion of Edgewise Therapeutics' stock is held by institutional investors, who collectively own 128,072,604 shares. This ownership structure reflects significant backing from entities that manage large investment portfolios. The company's history includes a notable $200 million underwritten offering of common stock in April 2025, which attracted participation from prominent life science investors and resulted in approximately 10.3% dilution for existing shareholders, while bolstering the company's financial capacity for advancing its clinical trials.

Key Institutional Shareholders in Edgewise Therapeutics

Several key institutional investors have demonstrated significant confidence in Edgewise Therapeutics' development pipeline and strategic direction. Their substantial holdings underscore their belief in the company's potential.

• Orbimed Advisors LLC holds 15,518,492 shares.
• RA Capital Management, L.P. has 9,902,633 shares.
• Baker Bros. Advisors LP owns 7,305,940 shares, representing 6.9% of outstanding shares as of August 14, 2025.
• BlackRock, Inc. possesses 6,781,046 shares.
• Paradigm Biocapital Advisors LP holds 6,142,344 shares.
• Janus Henderson Group Plc has 5,503,349 shares.
• Novo Holdings A/S owns 5,350,000 shares.
• Braidwell LP holds 5,210,831 shares.
• Vanguard Group Inc. possesses 4,841,500 shares.
• Perceptive Advisors LLC has 4,639,949 shares.

Understanding who owns Edgewise Therapeutics provides insight into the company's financial backing and the confidence placed in its future by major investment firms. The evolution of Edgewise Therapeutics ownership is a dynamic process, influenced by market conditions and company performance. For a deeper understanding of the company's journey, a Brief History of Edgewise Therapeutics offers valuable context.

Edgewise Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Edgewise Therapeutics is composed of key individuals representing both the company's founding vision and its significant investment base. This structure aims to balance founder expertise with the strategic oversight required by major shareholders and independent governance principles.

Edgewise Therapeutics operates under a standard one-share-one-vote system, common for companies listed on NASDAQ, meaning each share of common stock typically carries one vote. There is no public indication of dual-class share structures or special voting rights that would concentrate control. Beneficial ownership reports, such as a Schedule 13G/A filed on August 14, 2025, detail significant holdings; for instance, Baker Bros. Advisors LP reported beneficial ownership of 6.9% of the outstanding common stock, holding sole investment and voting power through its managed funds. This transparency in filings is crucial for understanding the distribution of voting power among Edgewise Therapeutics major shareholders. The company has not experienced notable proxy contests or activist campaigns recently, suggesting a stable governance framework.

Understanding Edgewise Therapeutics Ownership Structure

The ownership of Edgewise Therapeutics is shaped by its board composition and the voting power distribution among its shareholders. Key figures and institutional investors play a significant role in the company's direction.

• Founders and executive leadership are represented on the board.
• Major institutional investors, like OrbiMed and U.S. Venture Partners, have board representation.
• Independent directors ensure diverse perspectives and governance oversight.
• A one-share-one-vote structure governs voting power.
• Filings like Schedule 13G/A provide transparency on beneficial ownership.

Edgewise Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Edgewise Therapeutics has seen significant shifts in its ownership structure over the past few years, primarily following its public debut. The company's market capitalization reached approximately $1.47 billion by August 2025, reflecting its growth and market reception since going public in March 2021.

A substantial underwritten offering in April 2025, which generated approximately $200 million in gross proceeds, brought in significant investment from prominent life science investors. This event, while causing about 10.3% dilution for existing shareholders, considerably bolstered the company's financial resources for advancing its late-stage clinical trials. By June 30, 2025, Edgewise Therapeutics reported a strong cash reserve of roughly $594 million. Observing insider trading, several executives, including CEO Kevin Koch, CMO Joanne M. Donovan, and CSO Alan J. Russell, sold shares in August 2025 at an average price of $13.3924 per share. These transactions were mainly to cover statutory tax withholding obligations tied to Restricted Stock Unit (RSU) vesting, a common occurrence that doesn't necessarily signal a lack of confidence. As of August 18, 2025, there was a notable increase in institutional ownership, with 393 institutional owners holding shares. The company is poised for further developments, with key data readouts expected in late 2025, which could influence future investor sentiment and ownership trends.

Key Investors in Recent Financing

RA Capital Management, OrbiMed, and Perceptive Advisors were among the notable participants in the April 2025 offering, underscoring strong support from the life science investment community.

Financial Health Post-Offering

The company's cash position of approximately $594 million as of June 30, 2025, provides a solid foundation for funding ongoing clinical development and operations.

Insider Activity Context

Sales by executives in August 2025 were primarily for tax obligations related to RSU vesting, a standard practice for managing equity compensation.

Institutional Ownership Growth

The increase in the number of institutional owners to 393 by August 18, 2025, indicates growing interest and confidence from institutional investors in Edgewise Therapeutics.

Edgewise Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔